May 2, 2012
Evergreen Behavioral Solutions, Inc, of Middlebury, which does business as Vtrim®, recently raised an additional $250,000, completing its Series A funding round. According to CEO Krista M.C. Conley, "This funding supports Vtrim's current acceleration to widely disseminate online, expert-led, behavior modification programming for achieving and maintaining a healthy weight. We are building partnerships with institutions and individuals across America to deliver our clinical model for education and support that promotes a culture of eat less and move more.” Since licensing Vtrim in February 2011, the company has raised a total of $975,000 for commercialization activity. Read more
February 2012
In January, UVM became an affiliate of the Eli Lilly Open Innovation Drug Discovery Program (OIDD), a program created to increase Lilly's collaboration with academic institutes and to provide academic research centers a means to screen potentially therapeutic compounds in Lilly's proprietary assay system.
Lilly will screen compounds in a set of assay modules that include a primary phenotypic screening and secondary biochemical and cellular assays in the following areas:
For detailed information about Lilly's OIDD Program, and the science behind it, please click here. All submissions are confidential. There are no restrictions regarding the use of the Lilly report data. University researchers are free to publish and/or use the data in support of proposals to funding agencies. This service is provided for free to universities.
For more information or to submit your compounds, contact UVM's Office of Technology Commercialization at 656-8780 or ott@uvm.edu.